TEMP
AstraZeneca extends multi-year Oncology Data Alliance
Tempus AI and AstraZeneca have finalized a Fifth Amendment to extend their strategic oncology collaboration through the Renewal Term starting January 1, 2027. This secures continued cooperation in drug discovery, data integration, and clinical operations.